IP Library Granted Patent US 7,875,661
Granted Patent B2
US 7,875,661 · App. 11/954,090 · Granted Jan 25, 2011

Ordered polymer system and intraocular lens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,875,661
App. No.
11/954,090
Granted
Jan 25, 2011
Kind
B2
Abstract

An intraocular lens with an ordered polymer system contained within a lens capsule or a membrane in the lens capsule. The ordered polymer system includes at least one negatively charged copolymer comprising hydrophilic groups, anionic groups and hydrophobic groups, and at least one positively charged copolymer comprising hydrophilic groups, cationic groups and hydrophobic groups. The at least one negatively charged copolymer and the at least one positively charged copolymer are associatively arranged through non-covalent interactions in the lens capsule or the membrane.

Claims (51)

1. An intraocular lens comprising an ordered polymer system contained within a lens capsule or a membrane in the lens capsule, wherein the ordered polymer system comprises at least one negatively charged copolymer comprising hydrophilic groups, anionic groups and hydrophobic groups, and at least one positively charged copolymer comprising hydrophilic groups, cationic groups and hydrophobic groups, said at least one negatively charged copolymer and said at least one positively charged copolymer associatively arranged through non-covalent interactions in the lens capsule or the membrane resulting in the ordered polymer system, wherein the ordered polymer system is in the form of a gel of sufficient elasticity such that it can be deformed by the shear forces produced by the contraction and relaxation of the cillary muscles, and thereby provide for lens accommodation.

2. The lens of claim 1 wherein the at least one negatively charged copolymer and the at least one positively charged copolymer comprise side chains of methylene or a corresponding fluorinated side chains.

3. The lens of claim 1 wherein the at least one negatively charged copolymer is of formula I

wherein P is a pendant hydrophilic group; Q is a pendant hydrophobic group; and S is a pendant anionic group;

R′, R″, and R′″ are independently selected from hydrogen, fluorine, a C 1-3 alkyl or —(CH 2 ) k -phenyl (k is 0, 1, 2 or 3);

each of R a and R b is independently selected from hydrogen, fluorine or methyl;

l, m and n are integers from 1 to 6; and X, Y and Z are integers from 1 to 60.

4. The lens of claim 1 wherein the at least one positively charged copolymer is of formula II

wherein P is a pendant hydrophilic group; Q is a pendant hydrophobic group; and T is a pendant cationic group;

R′, R″, and R′″ are independently selected from hydrogen, fluorine, a C 1-3 alkyl or —(CH 2 ) k -phenyl (k is 0, 1, 2 or 3);

each of R a and R b is independently selected from hydrogen, fluorine or methyl;

l, m and n are integers from 1 to 6; and x, y and z are integers from 1 to 60.

5. The lens of claim 1 wherein the at least one positively charged copolymer is prepared with one or more monomers with at least one cationic group selected from the group consisting of primary, secondary, tertiary, and quaternary amino groups, sulfonium groups, guanidinium groups and phosphonium groups, and the corresponding salts thereof.

6. The lens of claim 1 wherein the at least one negatively charged copolymer is prepared with one or more monomers with at least one anionic group selected from the group consisting of carboxylic acids, sulfonic acids, sulfuric acids, sulfinic acids, phosphoric acids, phosphonic acids and phosphinic acids, and the corresponding salts thereof.

7. The lens of claim 1 wherein the at least one positively charged copolymer and the at least one negatively charged copolymer comprise a charge ratio from 2:1 to 1:2.

8. The lens of claim 7 wherein the charge ratio is from 1.2:1 to 1:1.2.

9. The lens of claim 1 further comprising an IOL substrate material that is embedded within the ordered polymer system.

10. An intraocular lens comprising an ordered polymer system contained within a lens capsule or a membrane in the lens capsule, wherein the ordered polymer system comprises at least one positively charged polyelectrolyte and at least one negatively charged polyelectrolyte with each of the polyelectrolytes having on average at least one ionic group for every four to sixteen carbon atoms along the copolymer backbone, said at least one negatively charged copolymer and said at least one positively charged copolymer associatively arranged through non-covalent interactions in the lens capsule or the membrane resulting in the ordered polymer system, wherein the ordered polymer system is in the form of a gel of sufficient elasticity such that it can be deformed by the shear forces produced by the contraction and relaxation of the cillary muscles, and thereby provide for lens accommodation.

11. The lens of claim 10 wherein the at least one positively charged polyelectrolyte is prepared with one or more monomers with at least one cationic group selected from the group consisting of primary, secondary, tertiary, and quaternary amino groups, sulfonium groups, guanidinium groups and phosphonium groups, and the corresponding salts thereof.

12. The lens of claim 10 wherein the at least one negatively charged copolymer is prepared with one or more monomers with at least one anionic group selected from the group consisting of carboxylic acids, sulfonic acids, sulfuric acids, sulfinic acids, phosphoric acids, phosphonic acids and phosphinic acids, and the corresponding salts thereof.

13. The lens of claim 10 wherein the at least one positively charged polyelectrolyte and the at least one negatively charged polyelectrolyte comprise a charge ratio from 2:1 to 1:2.

14. The lens of claim 13 wherein the charge ratio is from 1.2:1 to 1:1.2.

15. The lens of claim 10 further comprising an IOL substrate material that is embedded within the ordered polymer system.

16. A method of forming an intraocular lens in a lens capsule or a membrane positioned in the lens capsule, the method comprising:

providing at least one negatively charged copolymer comprising hydrophilic groups, anionic groups and hydrophobic groups, and at least one positively charged copolymer comprising hydrophilic groups, cationic groups and hydrophobic groups,

removing the natural lens form the lens capsule; and

injecting the at least one negatively charged copolymer and the at least one positively charged copolymer into the lens capsule or the membrane positioned in the lens capsule, resulting in an ordered polymer system, wherein the ordered polymer system is in the form of a gel of sufficient elasticity such that it can be deformed by the shear forces produced by the contraction and relaxation of the cillary muscles, and thereby provide for lens accommodation.

17. The method of claim 16 wherein the at least one negatively charged copolymer is of formula I and the at least one positively charged copolymer is of formula II

wherein P is a pendant hydrophilic group; Q is a pendant hydrophobic group; and S is a pendant anionic group; T is a pendant cationic group;

R′, R″, and R′″ are independently selected from hydrogen, fluorine, a C 1-3 alkyl or —(CH 2 ) k -phenyl (k is 0, 1, 2 or 3);

each of R a and R b is independently selected from hydrogen, fluoroine or methyl;

l, m and n are integers from 1 to 6; and x, y and z are integers from 1 to 60.

18. The method of claim 16 wherein the at least one positively charged copolymer and the at least one negatively charged copolymer comprise a charge ratio from 2:1 to 1:2.

19. The method of claim 16 further comprising inserting an IOL substrate material into the lens capsule or into the membrane positioned in the lens capsule.

20. A method of forming an intraocular lens in a lens capsule or a membrane positioned in the lens capsule, the method comprising:

providing at least one positively charged polyelectrolyte and at least one negatively charged polyelectrolyte with each of the polyelectrolytes having on average at least one ionic group for every four to sixteen carbon atoms along the copolymer backbone;

removing the natural lens form the lens capsule; and

injecting the at least one negatively charged polyelectrolyte and the at least one positively charged polyelectrolyte into the lens capsule or the membrane positioned in the lens capsule resulting in an ordered polymer system, wherein the ordered polymer system is in the form of a gel of sufficient elasticity such that it can be deformed by the shear forces produced by the contraction and relaxation of the cillary muscles, and thereby provide for lens accommodation.

21. The method of claim 20 wherein the at least one negatively charged polyelectrolyte is prepared from one or more monomers with at least one anionic group selected from the group consisting of carboxylic acids, sulfonic acids, sulfuric acids, sulfinic acids, phosphoric acids, phosphonic acids and phosphinic acids, and the corresponding salts thereof.

22. The method of claim 20 wherein the at least one positively charged polyelectrolyte is prepared with one or more monomers with at least one cationic group selected from the group consisting of primary, secondary, tertiary, and quaternary amino groups, sulfonium groups, guanidinium groups and phosphonium groups, and the corresponding salts thereof.

23. The method of claim 20 wherein the at least one positively charged polyelectrolyte and the at least one negatively charged polyelectrolyte comprise a charge ratio from 2:1 to 1:2.

24. The method of claim 20 further comprising inserting an IOL substrate material into the lens capsule or into the membrane positioned in the lens capsule.

25. The lens of claim 3 wherein the at least one positively charged copolymer is of formula II

wherein P is a pendant hydrophilic group; Q is a pendant hydrophobic group; and T is a pendant cationic group;

R′, R″, and R′″ are independently selected from hydrogen, fluorine, a C 1-3 alkyl or —(CH 2 ) k -phenyl (k is 0, 1, 2 or 3);

each of R a and R b is independently selected from hydrogen, fluorine or methyl;

l, m and n are integers from 1 to 6; and x, y and z are integers from 1 to 60.

26. The lens of claim 25 wherein the at least one positively charged copolymer is prepared with one or more monomers with at least one cationic group selected from the group consisting of primary, secondary, tertiary, and quaternary amino groups, sulfonium groups, guanidinium groups and phosphonium groups, and the corresponding salts thereof.

27. The lens of claim 26 wherein the at least one negatively charged copolymer is prepared with one or more monomers with at least one anionic group selected from the group consisting of carboxylic acids, sulfonic acids, sulfuric acids, sulfinic acids, phosphoric acids, phosphonic acids and phosphinic acids, and the corresponding salts thereof.

28. The lens of claim 1 comprising a refractive index of from 1.38 to 1.55.

29. The lens of claim 10 comprising a refractive index of from 1.38 to 1.55.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →